Abstract
Anti-TNF drugs may increase lymphoma risk in autoimmune rheumatic diseases, such as rheumatoid arthritis, but there have been no reports stating increased risk of lymphoma in ankylosing spondylitis (AS). Before 2 years, we had presented a case with AS developing Hodgkin's lymphoma following 6 months of etanercept treatment. Hereby, we present another case with AS developing non-Hodgkin's lymphoma (NHL), subsequent to 11 months of etanercept treatment. Pathological analysis revealed diffuse large B cell NHL. Although this is a report of a single case, cautious use of anti-TNF drugs is strongly recommended as they might cause lymphoma development even in AS.
MeSH terms
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / analogs & derivatives
-
Doxorubicin / therapeutic use
-
Etanercept
-
Humans
-
Immunoglobulin G / adverse effects*
-
Immunoglobulin G / therapeutic use*
-
Immunosuppressive Agents / adverse effects*
-
Immunosuppressive Agents / therapeutic use*
-
Leukopenia / chemically induced
-
Lymphoma, Non-Hodgkin / chemically induced*
-
Lymphoma, Non-Hodgkin / drug therapy
-
Lymphoma, Non-Hodgkin / pathology
-
Male
-
Middle Aged
-
Prednisone / therapeutic use
-
Receptors, Tumor Necrosis Factor / therapeutic use*
-
Rituximab
-
Splenomegaly / chemically induced
-
Splenomegaly / diagnostic imaging
-
Spondylitis, Ankylosing / drug therapy*
-
Thrombocytopenia / chemically induced
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
-
Ultrasonography
-
Vincristine / therapeutic use
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents
-
Immunoglobulin G
-
Immunosuppressive Agents
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Etanercept
-
Prednisone